Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495643 | 0.93 | EGLN1 (0.43) | CYP11B1CYP11B2EGLN1MAOBHTR6 | |
| SCHEMBL4807256 | 0.89 | HDAC1 (0.44) | CYP11B1CYP11B2MAOBHTR6MMP13 | |
| SCHEMBL3496747 | 0.87 | CYP11B1 (0.42) | CYP11B1CYP11B2MAOBLMNASMN1; SMN2 | |
| SCHEMBL14541609 | 0.82 | POLB (0.41) | CYP11B1CYP11B2EGLN1MAOBLMNA | |
| SCHEMBL4807840 | 0.82 | EGLN1 (0.58) | EGLN1MAOBLMNASMN1; SMN2RAB9A | |
| SCHEMBL28771833 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2MAOBHTR6LMNA | |
| SCHEMBL4803225 | 0.78 | EGLN1 (0.43) | CYP11B1CYP11B2EGLN1MAOBLMNA | |
| SCHEMBL4965274 | 0.78 | HSP90AA1 (0.42) | CYP11B1CYP11B2MAOBLMNACNR2 | |
| SCHEMBL3494864 | 0.77 | CNR2 (0.35) | CYP11B1CYP11B2MAOBCNR2TP53 | |
| SCHEMBL14302884 | 0.77 | TLR7 (0.34) | EGLN1LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| CN-101287735-A | Inhibitors of HIV integrase | PFIZER PROD INC (US) | 2008-10-15 | — | — | CN | disclosed |
| EP-1934220-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer Products Incorporated (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007042883-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | CYP11B1 1207/4885CYP11B2 1727/4885EGLN1 3711/4885 |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | CYP11B1 1207/4885CYP11B2 1727/4885EGLN1 3711/4885 |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | CYP11B1 1207/4885CYP11B2 1727/4885EGLN1 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.